Literature DB >> 14570592

Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event.

Adam Cole1, Sheelagh Frame, Philip Cohen.   

Abstract

Phosphorylation of the endogenous GSK3alpha (glycogen synthase kinase-3alpha) at Tyr279 and GSK3beta at Tyr216 was suppressed in HEK-293 or SH-SY5Y cells by incubation with pharmacological inhibitors of GSK3, but not by an Src-family inhibitor, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4- d ]pyrimidine (PP2), or a general protein tyrosine kinase inhibitor (genistein). GSK3beta transfected into HEK-293 cells or Escherichia coli became phosphorylated at Tyr216, but catalytically inactive mutants did not. GSK3beta expressed in insect Sf 21 cells or E. coli was extensively phosphorylated at Tyr216, but the few molecules lacking phosphate at this position could autophosphorylate at Tyr216 in vitro after incubation with MgATP. The rate of autophosphorylation was unaffected by dilution and was suppressed by the GSK3 inhibitor kenpaullone. Wild-type GSK3beta was unable to catalyse the tyrosine phosphorylation of catalytically inactive GSK3beta lacking phosphate at Tyr216. Our results indicate that the tyrosine phosphorylation of GSK3 is an intramolecular autophosphorylation event in the cells that we have studied and that this modification enhances the stability of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14570592      PMCID: PMC1223856          DOI: 10.1042/BJ20031259

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

1.  The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification.

Authors:  L Kim; J Liu; A R Kimmel
Journal:  Cell       Date:  1999-11-12       Impact factor: 41.582

Review 2.  The renaissance of GSK3.

Authors:  P Cohen; S Frame
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

3.  Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase.

Authors:  M Lesort; R S Jope; G V Johnson
Journal:  J Neurochem       Date:  1999-02       Impact factor: 5.372

4.  Tyrosine dephosphorylation of glycogen synthase kinase-3 is involved in its extracellular signal-dependent inactivation.

Authors:  H Murai; M Okazaki; A Kikuchi
Journal:  FEBS Lett       Date:  1996-08-26       Impact factor: 4.124

5.  Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216.

Authors:  M Shaw; P Cohen; D R Alessi
Journal:  FEBS Lett       Date:  1997-10-27       Impact factor: 4.124

6.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

7.  The specificities of protein kinase inhibitors: an update.

Authors:  Jenny Bain; Hilary McLauchlan; Matthew Elliott; Philip Cohen
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

8.  Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation.

Authors:  J H Hanke; J P Gardner; R L Dow; P S Changelian; W H Brissette; E J Weringer; B A Pollok; P A Connelly
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

9.  Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.

Authors:  Q M Wang; C J Fiol; A A DePaoli-Roach; P J Roach
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

10.  Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation.

Authors:  K Hughes; E Nikolakaki; S E Plyte; N F Totty; J R Woodgett
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

View more
  117 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

Review 2.  GSK3 signalling in neural development.

Authors:  Eun-Mi Hur; Feng-Quan Zhou
Journal:  Nat Rev Neurosci       Date:  2010-08       Impact factor: 34.870

3.  Chronic baclofen desensitizes GABA(B)-mediated G-protein activation and stimulates phosphorylation of kinases in mesocorticolimbic rat brain.

Authors:  Bradley M T Keegan; Thomas J R Beveridge; Jeffrey J Pezor; Ruoyu Xiao; Tammy Sexton; Steven R Childers; Allyn C Howlett
Journal:  Neuropharmacology       Date:  2015-02-25       Impact factor: 5.250

4.  S-nitrosoglutathione reduces tau hyper-phosphorylation and provides neuroprotection in rat model of chronic cerebral hypoperfusion.

Authors:  Je-Seong Won; Balasubramaniam Annamalai; Seungho Choi; Inderjit Singh; Avtar K Singh
Journal:  Brain Res       Date:  2015-08-10       Impact factor: 3.252

5.  Boosting CNS axon regeneration by harnessing antagonistic effects of GSK3 activity.

Authors:  Marco Leibinger; Anastasia Andreadaki; Renate Golla; Evgeny Levin; Alexander M Hilla; Heike Diekmann; Dietmar Fischer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

Review 6.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

7.  Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.

Authors:  Addolorata Maria Luce Coluccia; Angelo Vacca; Mireia Duñach; Luca Mologni; Sara Redaelli; Victor H Bustos; Daniela Benati; Lorenzo A Pinna; Carlo Gambacorti-Passerini
Journal:  EMBO J       Date:  2007-02-22       Impact factor: 11.598

8.  Tyr728 in the kinase domain of the murine kinase suppressor of RAS 1 regulates binding and activation of the mitogen-activated protein kinase kinase.

Authors:  Claudia Sibilski; Thomas Mueller; Laxmikanth Kollipara; René P Zahedi; Ulf R Rapp; Thomas Rudel; Angela Baljuls
Journal:  J Biol Chem       Date:  2013-10-24       Impact factor: 5.157

9.  Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

Authors:  Valentine Lahmy; Johann Meunier; Susanna Malmström; Gaelle Naert; Laurent Givalois; Seung Hyun Kim; Vanessa Villard; Alexandre Vamvakides; Tangui Maurice
Journal:  Neuropsychopharmacology       Date:  2013-03-14       Impact factor: 7.853

Review 10.  Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.

Authors:  P H Sugden; S J Fuller; S C Weiss; A Clerk
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.